Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 2, 2021

Primary Completion Date

October 9, 2025

Study Completion Date

July 1, 2026

Conditions

Extensive Stage Lung Small Cell Carcinoma

Interventions

BIOLOGICAL

Atezolizumab

Given IV

DRUG

Carboplatin

Given IV

DRUG

Etoposide

Given IV

DRUG

Lamivudine

Given PO

Trial Locations (1)

RECRUITING

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors

lead

Roswell Park Cancer Institute

OTHER